[{"address1": "6555 Carnegie Avenue", "address2": "4th Floor", "city": "Cleveland", "state": "OH", "zip": "44103", "country": "United States", "phone": "646 813 4701", "website": "https://www.abeonatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.", "fullTimeEmployees": 84, "companyOfficers": [{"maxAge": 1, "name": "Dr. Vishwas  Seshadri M.B.A., Ph.D.", "age": 47, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1490033, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph Walter Vazzano CPA", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 920853, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brendan M. O'Malley J.D., Ph.D.", "age": 53, "title": "Senior VP & General Counsel", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 802952, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Kevany Ph.D.", "title": "Senior VP, CTO & CSO", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory  Gin", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alison  Hardgrove", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jon  Voss", "age": 63, "title": "VP & Head of Quality", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhav  Vasanthavada M.B.A., Ph.D.", "title": "Senior VP, Chief Commercial Officer & Head of Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carl  Denny", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.accesspharma.com/investor-relations/", "maxAge": 86400, "priceHint": 2, "previousClose": 5.42, "open": 5.41, "dayLow": 4.81, "dayHigh": 5.54, "regularMarketPreviousClose": 5.42, "regularMarketOpen": 5.41, "regularMarketDayLow": 4.81, "regularMarketDayHigh": 5.54, "beta": 1.58, "forwardPE": -3.6258993, "volume": 1095723, "regularMarketVolume": 1095723, "averageVolume": 795324, "averageVolume10days": 553305, "averageDailyVolume10Day": 553305, "bid": 5.0, "ask": 5.05, "bidSize": 200, "askSize": 200, "marketCap": 206452000, "fiftyTwoWeekLow": 2.83, "fiftyTwoWeekHigh": 9.01, "priceToSalesTrailing12Months": 58.986286, "fiftyDayAverage": 4.5002, "twoHundredDayAverage": 5.2892, "currency": "USD", "enterpriseValue": 168402464, "floatShares": 29711995, "sharesOutstanding": 40962700, "sharesShort": 3359906, "sharesShortPriorMonth": 2288164, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.081999995, "heldPercentInsiders": 0.03238, "heldPercentInstitutions": 0.61283, "shortRatio": 7.05, "shortPercentOfFloat": 0.0848, "impliedSharesOutstanding": 41758100, "bookValue": -0.322, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -76659000, "trailingEps": -3.15, "forwardEps": -1.39, "lastSplitFactor": "1:25", "lastSplitDate": 1656979200, "enterpriseToRevenue": 48.115, "enterpriseToEbitda": -3.481, "52WeekChange": 0.35120642, "SandP52WeekChange": 0.22226071, "lastDividendValue": 3706.25, "lastDividendDate": 954460800, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ABEO", "underlyingSymbol": "ABEO", "shortName": "Abeona Therapeutics Inc.", "longName": "Abeona Therapeutics Inc.", "firstTradeDateEpochUtc": 883751400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6a7dfae4-c578-3526-bdcd-a5a90d9256dd", "messageBoardId": "finmb_360935", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.04, "targetHighPrice": 21.0, "targetLowPrice": 7.5, "targetMeanPrice": 16.42, "targetMedianPrice": 17.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 62344000, "totalCashPerShare": 1.514, "ebitda": -48374000, "totalDebt": 23169000, "quickRatio": 5.432, "currentRatio": 5.612, "totalRevenue": 3500000, "revenuePerShare": 0.146, "returnOnAssets": -0.49242002, "returnOnEquity": -15.55107, "freeCashflow": -21277624, "operatingCashflow": -39803000, "operatingMargins": -14.4262905, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-19"}]